Guidelines on diagnosis and treatment of pulmonary arterial hypertension
暂无分享,去创建一个
A. Torbicki | R. Barst | G. Simonneau | H. Olschewski | L. Rubin | T. Higenbottam | A. Peacock | N. Galiè | P. Dartevelle | S. Haworth | Giuseppe Pietra | L. J. Rubin | G. Simonneau | Gianfranco Mazzotta | O. Smiseth | Tim Higenbottam | A. Budaj | Sheila Haworth | Horst Olschewski | Andrew Peacock
[1] K. Meyer,et al. Bronchoalveolar lavage as a diagnostic tool. , 2007, Seminars in respiratory and critical care medicine.
[2] M. Humbert,et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2 , 2004, European Respiratory Journal.
[3] S. Rich,et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.
[4] D. Mccrory,et al. Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines , 2004 .
[5] M. Humbert,et al. Pulmonary hypertension: CT of the chest in pulmonary venoocclusive disease. , 2004, AJR. American journal of roentgenology.
[6] M. Humbert,et al. Pathologic assessment of vasculopathies in pulmonary hypertension. , 2004, Journal of the American College of Cardiology.
[7] M. Humbert,et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[8] A. Torbicki,et al. Diagnosis and differential assessment of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[9] P. Corris,et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[10] A. Fishman. Primary pulmonary arterial hypertension: a look back. , 2004, Journal of the American College of Cardiology.
[11] W. Seeger,et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[12] A. Torbicki,et al. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. , 2004, Journal of the American College of Cardiology.
[13] R. Naeije,et al. End points in pulmonary arterial hypertension: the way forward , 2004, European Respiratory Journal.
[14] M. Humbert,et al. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension , 2004, Thorax.
[15] B. Raju,et al. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.
[16] R. D. du Bois,et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. , 2004, Rheumatology.
[17] R. Dixon,et al. Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.
[18] A. Branzi,et al. The endothelin system in pulmonary arterial hypertension. , 2004, Cardiovascular research.
[19] R. Budhiraja,et al. Endothelial Dysfunction in Pulmonary Hypertension , 2004, Circulation.
[20] H. Kauczor,et al. Assessment of pulmonary hypertension by CT and MR imaging , 2004, European Radiology.
[21] G. Simonneau,et al. [Pulmonary hypertension: CT findings in pulmonary veno-occlusive disease]. , 2003, Journal de radiologie.
[22] C. Denton,et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach , 2003, Annals of the rheumatic diseases.
[23] S. Archer,et al. Long-Term Treatment With Oral Sildenafil Is Safe and Improves Functional Capacity and Hemodynamics in Patients With Pulmonary Arterial Hypertension , 2003, Circulation.
[24] M. Mcgoon,et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. , 2003, Mayo Clinic proceedings.
[25] A. Torbicki,et al. Detectable Serum Cardiac Troponin T as a Marker of Poor Prognosis Among Patients With Chronic Precapillary Pulmonary Hypertension , 2003, Circulation.
[26] M. Hoeper,et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids , 2003, European Respiratory Journal.
[27] W. Seeger,et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[28] D. Badesch,et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. , 2003, Chest.
[29] K. Wasserman,et al. Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[30] A. Branzi,et al. Women and pulmonary arterial hypertension , 2003 .
[31] A. Parkhomenko,et al. Management of grown up congenital heart disease. , 2003, European heart journal.
[32] M. Humbert,et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. , 2003, American journal of respiratory and critical care medicine.
[33] G. Funk,et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. , 2003, The Journal of clinical investigation.
[34] A. Torbicki,et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.
[35] W. Seeger,et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. , 2003, American journal of respiratory and critical care medicine.
[36] R. Barst,et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension , 2003, Clinical pharmacology and therapeutics.
[37] J. Newman,et al. Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. , 2003, American journal of respiratory and critical care medicine.
[38] A. Branzi,et al. Effects of sildenafil on growth and viability of cultured human pulmonary artery smooth muscle cells , 2003 .
[39] P. Arbogast,et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. , 2003, American journal of respiratory and critical care medicine.
[40] O. Castro,et al. Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. , 2003, Blood.
[41] P. Thistlethwaite,et al. Signaling molecules in nonfamilial pulmonary hypertension. , 2003, The New England journal of medicine.
[42] S. Rich,et al. Efficacy and Safety of Treprostinil: An Epoprostenol Analog for Primary Pulmonary Hypertension , 2003, Journal of cardiovascular pharmacology.
[43] T. Shim,et al. Clinical Manifestations of Pulmonary Infection Due to Rapidly Growing Nontuberculous Mycobacteri , 2003 .
[44] A. Branzi,et al. Prostanoids for Pulmonary Arterial Hypertension , 2003, American journal of respiratory medicine : drugs, devices, and other interventions.
[45] S. Chuncharunee,et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. , 2003, International journal of hematology.
[46] D. Blondheim,et al. Expert consensus document on management of cardiovascular diseases during pregnancy. , 2003, European heart journal.
[47] D. Badesch,et al. Pulmonary hypertension associated with connective tissue disease. , 2002, Progress in cardiovascular diseases.
[48] A. Branzi,et al. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension , 2002, European Respiratory Journal.
[49] W. Seeger,et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial , 2002, The Lancet.
[50] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[51] R. Barst,et al. Eisenmenger's syndrome: current management. , 2002, Progress in cardiovascular diseases.
[52] E. Trulock,et al. The registry of the international society for heart and lung transplantation: nineteenth official report-2002. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[53] I. Khan,et al. Acute Coronary Syndrome in Patients with Human Immunodeficiency Virus Disease , 2002, Angiology.
[54] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[55] J. Greenfield,et al. Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular disease. , 2002, Chest.
[56] W. Seeger,et al. Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.
[57] C. Lavie,et al. Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects. , 2002, Circulation.
[58] R. Hetzer,et al. Assessment of Survival in Patients With Primary Pulmonary Hypertension: Importance of Cardiopulmonary Exercise Testing , 2002, Circulation.
[59] M. Humbert,et al. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis , 2002, European Respiratory Journal.
[60] S. Rich,et al. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. , 2002, Chest.
[61] G. Simonneau,et al. New treatments for pulmonary arterial hypertension. , 2002, American journal of respiratory and critical care medicine.
[62] M. Humbert,et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.
[63] R. Barst,et al. Transitioning From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension , 2002 .
[64] G. Koch,et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. , 2002, Journal of the American College of Cardiology.
[65] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[66] G. Verleden,et al. Combined liver and (heart-)lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. , 2002, Transplantation.
[67] M. Krowka. Hepatopulmonary syndrome and portopulmonary hypertension , 2001, Current treatment options in cardiovascular medicine.
[68] R. Barst,et al. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. , 2002, Chest.
[69] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[70] R. Speich,et al. Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.
[71] Arthur E. Weyman,et al. Clinical Correlates and Reference Intervals for Pulmonary Artery Systolic Pressure Among Echocardiographically Normal Subjects , 2001, Circulation.
[72] R. Speich,et al. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. , 2001, Swiss medical weekly.
[73] J. Sandoval,et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. , 2001, American journal of respiratory and critical care medicine.
[74] R. Ewert,et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. , 2001, Chest.
[75] M. Humbert,et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. , 2001, The Journal of clinical investigation.
[76] M. Humbert,et al. Risk factors for pulmonary arterial hypertension. , 2001, Clinics in chest medicine.
[77] E. Stork,et al. Persistent pulmonary hypertension of the newborn. Rational therapy based on pathophysiology. , 2001, Clinics in perinatology.
[78] A. Oberg,et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. , 2001, Chest.
[79] J. Sandoval,et al. Atrial septostomy for pulmonary hypertension. , 2001, Clinics in chest medicine.
[80] R. Naeije,et al. Medical therapy of pulmonary hypertension. Conventional therapies. , 2001, Clinics in chest medicine.
[81] M. Humbert,et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. , 2001, The New England journal of medicine.
[82] B. Winters,et al. Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[83] W F Walsh,et al. Neonatal pulmonary hypertension--urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function. , 2001, The New England journal of medicine.
[84] M. Katayama,et al. [Pulmonary hypertension in patients with connective tissue diseases]. , 2001, Nihon rinsho. Japanese journal of clinical medicine.
[85] M. Rubenfire,et al. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. , 2001, The European respiratory journal.
[86] Jürg Reichen,et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions , 2001, Clinical pharmacology and therapeutics.
[87] C. Denton,et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. , 2001, Rheumatology.
[88] R. Pauwels,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.
[89] D. Badesch,et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[90] M. Stewart,et al. Group support for couples coping with a cardiac condition. , 2001, Journal of advanced nursing.
[91] N. Galiè. Do we need controlled clinical trials in pulmonary arterial hypertension? , 2001, The European respiratory journal.
[92] R. Trembath,et al. Primary pulmonary hypertension: the pressure rises for a gene , 2000, Journal of clinical pathology.
[93] E. Ely,et al. Pulmonary veno-occlusive disease: a case series and new observations. , 2000, Chest.
[94] M. Gatzoulis,et al. Sildenafil in primary pulmonary hypertension. , 2000, The New England journal of medicine.
[95] R. Hetzer,et al. [Iloprost as inhalational and intravenous long-term treatment of patients with primary pulmonary hypertension. Register of the Berlin Study Group for Pulmonary Hypertension]]. , 2000, Zeitschrift fur Kardiologie.
[96] H. Farber,et al. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. , 2000, American journal of respiratory and critical care medicine.
[97] I. Khan,et al. HIV-Related pulmonary hypertension: analytic review of 131 cases. , 2000, Chest.
[98] S. Hodge,et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. , 2000, American journal of human genetics.
[99] R. Trembath,et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension , 2000, Nature Genetics.
[100] K. Kangawa,et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.
[101] A. Magee,et al. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension , 2000, Heart.
[102] R. Wiesner,et al. Pulmonary hemodynamics and perioperative cardiopulmonary‐related mortality in patients with portopulmonary hypertension undergoing liver transplantation , 2000, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[103] M. Hoeper,et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. , 2000, The New England journal of medicine.
[104] J. Thumboo,et al. Primary and secondary pulmonary hypertension in systemic lupus erythematosus , 2000, Lupus.
[105] Adrian M Heilbut,et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor , 2000, Nature Medicine.
[106] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[107] M. Keszler,et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. , 2000, The New England journal of medicine.
[108] L. Hillis,et al. Congenital heart disease in adults : Second of two parts , 2000 .
[109] M. Fujita,et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.
[110] L. Hillis,et al. Congenital heart disease in adults: First of two parts , 2000 .
[111] B. Groves,et al. Hyperuricemia in severe pulmonary hypertension. , 2000, Chest.
[112] R. Lark,et al. LOW-DOSE NITRIC OXIDE THERAPY FOR PERSISTENT PULMONARY HYPERTENSION OF THE NEWBORN , 2000 .
[113] Inda,et al. A COMPARISON OF CONTINUOUS INTRAVENOUS EPOPROSTENOL ( PROSTACYCLIN ) WITH CONVENTIONAL THERAPY FOR PRIMARY PULMONARY HYPERTENSION , 2000 .
[114] R A Nishimura,et al. Assessment of right atrial pressure with 2-dimensional and Doppler echocardiography: a simultaneous catheterization and echocardiographic study. , 2000, Mayo Clinic proceedings.
[115] W. Seeger,et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. , 2000, Journal of the American College of Cardiology.
[116] J. Loyd,et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. , 2000, Chest.
[117] L. Rubin,et al. Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease. , 1999, Chest.
[118] J. Findlay,et al. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. , 1999, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[119] R. Wiesner,et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension , 1999, Hepatology.
[120] W. Seeger,et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. , 1999, American journal of respiratory and critical care medicine.
[121] P. Lange,et al. Incidence of secondary pulmonary hypertension in adults with atrial septal or sinus venosus defects , 1999, Heart.
[122] A. Chaouat,et al. Improvement of pulmonary hypertension after liver transplantation. , 1999, Chest.
[123] J. Corbin,et al. Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.
[124] Thomas Albrecht,et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent , 1999, The Lancet.
[125] S. Rich,et al. Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series , 1999, Annals of Internal Medicine.
[126] R. Barst,et al. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. , 1999, Circulation.
[127] P. Flemming,et al. Pulmonary Hypertension after Splenectomy? , 1999, Annals of Internal Medicine.
[128] G. Maislin,et al. Vasodilator therapy for primary pulmonary hypertension in children. , 1999, Circulation.
[129] J. Roos‐Hesselink,et al. [Eisenmenger syndrome in adults]. , 1999, Nederlands tijdschrift voor geneeskunde.
[130] M. Humbert,et al. Treatment of pulmonary hypertension secondary to connective tissue diseases , 1999, Thorax.
[131] M. Humbert,et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. , 1999, The European respiratory journal.
[132] P. Presbitero,et al. Eisenmenger syndrome. Factors relating to deterioration and death. , 1998, European heart journal.
[133] R. Naeije,et al. False-positive diagnosis of pulmonary hypertension by Doppler echocardiography. , 1998, European Respiratory Journal.
[134] S. Rybalkin,et al. Chronic pulmonary hypertension increases fetal lung cGMP phosphodiesterase activity. , 1998, American journal of physiology. Lung cellular and molecular physiology.
[135] M. Humbert,et al. High-resolution CT of the chest in four patients with pulmonary capillary hemangiomatosis or pulmonary venoocclusive disease. , 1998, AJR. American journal of roentgenology.
[136] J. Orens,et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. , 1998, Circulation.
[137] J. Somerville,et al. Small ventricular septal defects in adults. , 1998, European heart journal.
[138] N. Voelkel,et al. Primary pulmonary hypertension between inflammation and cancer. , 1998, Chest.
[139] S. Rich,et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. , 1998, Chest.
[140] A. Branzi,et al. Primary Pulmonary Hypertension , 1998 .
[141] M. Humbert,et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. , 1998, The European respiratory journal.
[142] L. Sharples,et al. Long term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension , 1998, Heart.
[143] J. Sandoval,et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. , 1998, Journal of the American College of Cardiology.
[144] J. W. Miller,et al. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. , 1998, American journal of respiratory and critical care medicine.
[145] O. Hess,et al. Outcome of pulmonary vascular disease in pregnancy: a systematic overview from 1978 through 1996. , 1998, Journal of the American College of Cardiology.
[146] J B Seward,et al. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. , 1998, The American journal of cardiology.
[147] M. Humbert,et al. Pulmonary vascular disorders in portal hypertension. , 1998, The European respiratory journal.
[148] M. Humbert,et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. , 1998, American journal of respiratory and critical care medicine.
[149] Y. Kawaguchi,et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. , 1998, Biochemical and biophysical research communications.
[150] M. Humbert,et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. , 1998, The European respiratory journal.
[151] C. Howell,et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. , 1998, Transplantation.
[152] T. Higenbottam,et al. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost , 1998, Heart.
[153] S. Rich,et al. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. , 1998, The New England journal of medicine.
[154] L. Rubin,et al. Primary pulmonary hypertension. , 1997, The New England journal of medicine.
[155] T. Bashore,et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. , 1998, Chest.
[156] R. Barst,et al. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. , 1997, Circulation.
[157] C. Howell,et al. Distinctive clinical features of portopulmonary hypertension. , 1997, Chest.
[158] F. Martinez,et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. , 1997, AJR. American journal of roentgenology.
[159] H P Gurtner,et al. The effect of anticoagulant therapy in primary and anorectic drug-induced pulmonary hypertension. , 1997, Chest.
[160] G. Koch,et al. Effects of Long-term Infusion of Prostacyclin (Epoprostenol) on Echocardiographic Measures of Right Ventricular Structure and Function in Primary Pulmonary Hypertension , 1997 .
[161] R. Speich,et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. , 1997, American journal of respiratory and critical care medicine.
[162] C. Howell,et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. , 1997, Transplantation.
[163] A. Wells,et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. , 1997, British journal of rheumatology.
[164] E. Beutler,et al. Pulmonary Hypertension Developing after Alglucerase Therapy in Two Patients with Type 1 Gaucher Disease Complicated by the Hepatopulmonary Syndrome , 1996, Annals of Internal Medicine.
[165] J. Seward,et al. Frequency of Doppler measurable pulmonary artery pressures. , 1996, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[166] A J Tajik,et al. Doppler echocardiographic index for assessment of global right ventricular function. , 1996, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[167] S. Swensen,et al. Pulmonary venoocclusive disease: CT findings in eight patients. , 1996, AJR. American journal of roentgenology.
[168] J Benichou,et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. , 1996, The New England journal of medicine.
[169] G. Simonneau,et al. Clinical significance of the pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. , 1996, Circulation.
[170] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[171] E. Trulock,et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[172] J. Polson,et al. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. , 1996, Annual review of pharmacology and toxicology.
[173] K. Morris,et al. Inhibition of cyclic 3'-5'-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. , 1996, The Journal of clinical investigation.
[174] S. Rich,et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. , 1995, Journal of the American College of Cardiology.
[175] C. Benjamin,et al. Activation of thromboxane and prostacyclin receptors elicits opposing effects on vascular smooth muscle cell growth and mitogen-activated protein kinase signaling cascades. , 1995, Molecular pharmacology.
[176] R. Sanson-Fisher,et al. Breaking bad news: consensus guidelines for medical practitioners. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[177] O. Alfieri,et al. [Pulmonary thromboendarterectomy in the surgical treatment of chronic thromboembolic pulmonary hypertension. First Italian experience]. , 1995, Cardiologia.
[178] M. Mcgoon. Medical treatment of pulmonary hypertension. , 1995, Cardiologia.
[179] K. Stenmark,et al. Persistent pulmonary hypertension of the newborn. , 1995, American journal of respiratory and critical care medicine.
[180] D. Mitchell,et al. AIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals. , 1995, Thorax.
[181] J. Sandoval,et al. Primary pulmonary hypertension in children: clinical characterization and survival. , 1995, Journal of the American College of Cardiology.
[182] J. Golden,et al. Do patients with primary pulmonary hypertension develop extensive central thrombi? , 1995, Circulation.
[183] A. Branzi,et al. Role of pharmacologic tests in the treatment of primary pulmonary hypertension. , 1995, The American journal of cardiology.
[184] G. Simonneau,et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. , 1994, Circulation.
[185] E. Wouters,et al. The International Primary Pulmonary Hypertension Study (IPPHS). , 1994, Chest.
[186] B. Groves,et al. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. , 1994, The American journal of pathology.
[187] I. Frank,et al. Pulmonary aspergillosis in patients with AIDS. Clinical and radiographic correlations. , 1994, Chest.
[188] D. Stewart,et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. , 1993, The New England journal of medicine.
[189] S. Rich,et al. Short-term effectiveness of nifedipine in secondary pulmonary hypertension. , 1993, The American journal of cardiology.
[190] J. Coligan,et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. , 1993, Journal of immunology.
[191] S. Rich,et al. Successful management of labor and delivery in primary pulmonary hypertension. , 1993, The American journal of cardiology.
[192] R. R. Wolfe,et al. Second natural history study of congenital heart defects. Results of treatment of patients with ventricular septal defects. , 1993, Circulation.
[193] G. Gray,et al. In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology. , 1993, Journal of cardiovascular pharmacology.
[194] B. Groves,et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. , 1992, The New England journal of medicine.
[195] S. Rich,et al. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. , 1992, The New England journal of medicine.
[196] H. Palevsky,et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. , 1992, The American review of respiratory disease.
[197] S. Rich,et al. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: guidelines for short-term drug testing. , 1991, Journal of the American College of Cardiology.
[198] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[199] D. Stewart,et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? , 1991, Annals of internal medicine.
[200] A. Hadengue,et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. , 1991, Gastroenterology.
[201] D. Moodie,et al. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. , 1991, Journal of the American College of Cardiology.
[202] G. Lister. Persistent Pulmonary Hypertension of the Newborn , 1991, International Journal of Technology Assessment in Health Care.
[203] J. Hageman,et al. National survey of diagnosis and management of persistent pulmonary hypertension of the newborn. , 1990, Journal of perinatology : official journal of the California Perinatal Association.
[204] A. Jaffe,et al. Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension. , 1990, Circulation.
[205] J. H. Diehl,et al. Treatment of Primary Pulmonary Hypertension with Continuous Intravenous Prostacyclin (Epoprostenol): Results of a Randomized Trial , 1990 .
[206] B. Groves,et al. Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry. , 1989, Circulation.
[207] N. Reichek,et al. Two-dimensional and Doppler-echocardiographic and cardiac catheterization correlates of survival in primary pulmonary hypertension. , 1989, Circulation.
[208] B. Groves,et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension. , 1989, The American review of respiratory disease.
[209] J. Rouleau,et al. Familial pulmonary capillary hemangiomatosis resulting in primary pulmonary hypertension. , 1988, Annals of internal medicine.
[210] D. Buff. Primary pulmonary hypertension. , 1987, Annals of internal medicine.
[211] D. G. Ritter,et al. Isolated atrial septal defect with pulmonary vascular obstructive disease--long-term follow-up and prediction of outcome after surgical correction. , 1987, Circulation.
[212] E H Bergofsky,et al. Primary pulmonary hypertension. A national prospective study. , 1987, Annals of internal medicine.
[213] B. Brundage,et al. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. , 1987, Circulation.
[214] B. Brundage,et al. Antinuclear antibodies in primary pulmonary hypertension. , 1986, Journal of the American College of Cardiology.
[215] C. Oakley,et al. Factors that influence the outcome of primary pulmonary hypertension. , 1986, British heart journal.
[216] G. Guyatt,et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.
[217] V. Fuster,et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. , 1984, Circulation.
[218] G. Hutchins,et al. Primary pulmonary hypertension and cirrhosis: are they related? , 2015, The American review of respiratory disease.
[219] D. Nelson,et al. Peripartum Heart Failure Due to Primary Pulmonary Hypertension , 1983, Obstetrics and gynecology.
[220] B. Magnani,et al. [Precapillary pulmonary hypertension: effect of Captopril]. , 1982, Giornale italiano di cardiologia.
[221] R. Niedermann,et al. Plexogenic pulmonary arteriopathy and liver cirrhosis. , 1980, Thorax.
[222] D. Dhumeaux,et al. Pulmonary hypertension complicating portal hypertension. , 1979, The American review of respiratory disease.
[223] D. Dhumeaux,et al. Pulmonary hypertension complicating portal hypertension. , 1979, The American review of respiratory disease.
[224] J. Ochsner,et al. Congenital Heart Disease in Adults , 1967, Southern medical journal.
[225] A. Rudolph,et al. The natural history of ventricular septal defects in infancy. , 1965, The American journal of cardiology.
[226] W. Austen,et al. EXPERIMENTAL STUDIES OF THE SURGICAL TREATMENT OF PRIMARY PULMONARY HYPERTENSION. , 1964, The Journal of thoracic and cardiovascular surgery.
[227] E. Besterman. ATRIAL SEPTAL DEFECT WITH PULMONARY HYPERTENSION , 1961, British heart journal.
[228] P. Wood. PULMONARY HYPERTENSION WITH SPECIAL REFERENCE TO THE VASOCONSTRICTIVE FACTOR* , 1958, British heart journal.